Oliceridine for Gastrointestinal Dysfunction (NCT07650812) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Oliceridine for Gastrointestinal Dysfunction
176 participantsStarted 2026-07-01
Plain-language summary
Gastrointestinal dysfunction is common in patients after major surgery, especially for neurosurgery. It was reported 80% of neurosurgery patients could be combined with gastrointestinal dysfunction, and it may relate to old age, surgery time, and factors of anesthesia and surgery. Meanwhile, postoperative constipation, nausea, and vomiting induced by gastrointestinal dysfunction may increase the intracranial bleeding. Oliceridine could activate mu opioid receptors without the interaction of (beta)arr2-muOR, and may reduce the gastrointestinal dysfunction, but a limited study has illustrated this topic. Thus, this study is conducted to explore whether oliceridine could reduce the gastrointestinal dysfunction vs. sufentanil in patients undergoing neurosurgery.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients undergoing selective neurosurgical resection of craniocerebral tumors;
* Age ≥ 18 years old;
* American Society of Anesthesiologists (ASA) grade 1-3;
* Sign the informed consent form.
Exclusion Criteria:
* Patients unable to complete scale assessment due to preoperative language dysfunction or communication impairment;
* Patients with preoperative symptoms of posterior cranial nerve injury and who need to retain a tracheal tube;
* Patients with insular, brainstem, or medullary lesions that may impair early postoperative recovery of consciousness;
* Patients undergoing intracranial lesion resection via the transsphenoidal approach;
* Patients with a history of previous abdominal surgery;
* Patients with BMI \> 35.0 kg/m2;
* Patients with liver or kidney dysfunction;
* Patients with a history of allergic or adverse reactions to the test drug;
* Patients with a history of drug abuse;
* Pregnant or lactating women.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.